P
Paul L. Nguyen
Researcher at Brigham and Women's Hospital
Publications - 566
Citations - 21624
Paul L. Nguyen is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 64, co-authored 526 publications receiving 17158 citations. Previous affiliations of Paul L. Nguyen include Beth Israel Deaconess Medical Center & American College of Radiology.
Papers
More filters
Journal ArticleDOI
Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy
Paul L. Nguyen,Alphonse G. Taghian,Matthew S. Katz,Andrzej Niemierko,Rita Abi Raad,Whitney L. Boon,Jennifer R. Bellon,Julia S. Wong,Barbara L. Smith,Jay R. Harris +9 more
TL;DR: Overall, the 5-year local recurrence rate after BCT was low, but varied by subtype as approximated using ER, PR, and HER-2 status, which may be useful in counseling patients about their anticipated outcome after B CT.
Journal ArticleDOI
Marital Status and Survival in Patients With Cancer
Ayal A. Aizer,Ming-Hui Chen,Ellen P. McCarthy,Mallika L. Mendu,Sophia Koo,Tyler J. Wilhite,Powell L. Graham,Toni K. Choueiri,Karen E. Hoffman,Neil E. Martin,Jim C. Hu,Paul L. Nguyen +11 more
TL;DR: Even after adjusting for known confounders, unmarried patients are at significantly higher risk of presentation with metastatic cancer, undertreatment, and death resulting from their cancer.
Journal ArticleDOI
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Paul L. Nguyen,Shabbir M.H. Alibhai,Shehzad Basaria,Anthony V. D'Amico,Philip W. Kantoff,Nancy L. Keating,David F. Penson,Derek J. Rosario,Bertrand Tombal,Matthew R. Smith +9 more
TL;DR: ADT is often a necessary component of the treatment of aggressive prostate cancer, yet it has known harms that can impair health and quality of life.
Journal ArticleDOI
Fatty acid synthase as a potential therapeutic target in cancer
TL;DR: Overexpression of FASN is common in many cancers, and accumulating evidence suggests that it is a metabolic oncogene with an important role in tumor growth and survival, making it an attractive target for cancer therapy.
Journal ArticleDOI
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
W. Robert Lee,James J. Dignam,Mahul B. Amin,Deborah Watkins Bruner,Daniel A. Low,Gregory P. Swanson,Amit Shah,David D'Souza,Jeff M. Michalski,Ian S. Dayes,Samantha A. Seaward,William A. Hall,Paul L. Nguyen,Thomas M. Pisansky,Sergio Faria,Yuhchyau Chen,Bridget F. Koontz,Rebecca Paulus,Howard M. Sandler +18 more
TL;DR: In men with low-risk prostate cancer, the efficacy of 70 Gy in 28 fractions over 5.6 weeks is not inferior to 73.8 Gy in 41 fractions over 8.2 weeks, although an increase in late GI/genitourinary adverse events was observed in patients treated with H-RT.